ADAM17在乳腺癌组织中的表达及意义

Expression of ADAM17 in tissue of breast cancer and its clinical significance

目的探讨解聚素-金属蛋白酶17(ADAM17)在乳腺癌中的表达及临床意义。方法采用免疫组化及免疫印迹2种方法检测ADAM17蛋白在乳腺癌、乳腺纤维腺瘤及正常乳腺组织中的表达情况,并分析其在这三者中的表达差异。结果免疫组化结果显示ADAM17主要在胞浆表达。其在正常乳腺组织中呈阴性表达,在乳腺纤维腺瘤组织部分呈弱阳性表达(54.5%),部分呈阴性表达(45.5%),但乳腺癌组织中ADAM17以强阳性表达为主(69.2%)。乳腺癌与乳腺纤维腺瘤、乳腺癌与正常乳腺组织之间的ADAM17表达均有显著性差异。免疫印迹结果显示,与正常乳腺组织相比,乳腺纤维腺瘤组织中ADAM17表达轻度增高,在乳腺癌表达却显著增高;乳腺癌中的ADAM17表达水平明显高于乳腺纤维腺瘤,有显著性差异。结论 ADAM17在纤维腺瘤中呈低表达,而在乳腺癌中却是高表达,因此ADAM17的表达水平可作为临床诊断乳腺癌的一个新的辅助指标,并可成为一个新的乳腺癌靶向治疗的靶点。

Objective It is to approach the expression of ADAM17 in breast cancer and its clinical significance.Methods The expressions of ADAM17 in the tissue of breast cancer,fibroadenoma and normal breast tissue were detected with immunohistochemisty and immunoblotting.The differences of ADAM17 expressions among them were analyzed.Results Immunohistochemisty results showed that there was no ADAM17 expression in normal breast tissue,a weakly expression in fibroadenoma and high expression in breast cancer which located in cytoplasm.It was a similar found detected with immunoblotting that ADAM-17 protein had very low expression in normal tissue and a little bit increases in fibroadenoma,however it was significantly up-regulated in breast cancer.Conclusion There is a weak expression of ADAM17 in fibroadenoma while high in breast cancer.Therefore,high levels of ADAM17 can be used as a new indicator to diagnose breast cancer in clinic and a new target gene to treat breast cancer.